Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Autor: Richardson, Debra L., Moore, Kathleen N., Vergote, Ignace, Gilbert, Lucy, Martin, Lainie P., Mantia-Smaldone, Gina M., Castro, Cesar M., Provencher, Diane, Matulonis, Ursula A., Stec, James, Wang, Yuemei, Method, Michael, O'Malley, David M.
Zdroj: In Gynecologic Oncology June 2024 185:186-193
Databáze: ScienceDirect
Externí odkaz: